A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Latest Information Update: 11 Jul 2024
At a glance
- Drugs Bendamustine (Primary) ; Gemcitabine (Primary) ; Oxaliplatin (Primary) ; Rituximab (Primary) ; Zilovertamab vedotin (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 19 Apr 2024 Planned number of patients changed from 420 to 260.
- 19 Apr 2024 Planned End Date changed from 16 Dec 2025 to 21 Jun 2027.
- 19 Apr 2024 Planned primary completion date changed from 16 Dec 2025 to 21 Jun 2027.